摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-{2-[5-methyl-2-(4-fluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-6-difluoromethoxy-benzoic acid | 632624-80-7

中文名称
——
中文别名
——
英文名称
3-{2-[5-methyl-2-(4-fluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-6-difluoromethoxy-benzoic acid
英文别名
3-{2-[5-methyl-2-(4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-5-difluoromethoxybenzoic acid;2-(difluoromethoxy)-5-[2-[2-[(4-fluorophenyl)methoxy]-5-methylphenyl]-5-methylpyrrol-1-yl]benzoic acid
3-{2-[5-methyl-2-(4-fluoro-benzyloxy)-phenyl]-5-methyl-pyrrol-1-yl}-6-difluoromethoxy-benzoic acid化学式
CAS
632624-80-7
化学式
C27H22F3NO4
mdl
——
分子量
481.471
InChiKey
SNDJLNHSJFIPIQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.8
  • 重原子数:
    35
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    60.7
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrrole compounds for the treatment of prostaglandine mediated diseases
    申请人:Giblin Martin Paul Gerard
    公开号:US20070082912A1
    公开(公告)日:2007-04-12
    Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R 1 , R 2a , R 2b , R x , R 8 , and R 9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    化合物的公式(I)或其药学上可接受的衍生物: 其中A,R1,R2a,R2b,Rx,R8和R9如规范中所定义,制备这种化合物的方法,包含这种化合物的药物组合物以及这种化合物在医学上的使用。
  • Treatment of BPH
    申请人:Newgreen Thomas Donald
    公开号:US20050020646A1
    公开(公告)日:2005-01-27
    The present invention relates to the use of EP1 receptor antagonists for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The invention also includes screening methods to identify compounds useful for the treatment of LUTS associated with BPH.
  • [EN] EP1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND SCREENING METHOD<br/>[FR] ANTAGONISTES DU RECEPTEUR DE EP1 POUR LE TRAITEMENT DE L'HYPERTROPHIE BENIGNE DE LA PROSTATE EST ET DE DEPISTAGE
    申请人:PFIZER LTD
    公开号:WO2005010534A1
    公开(公告)日:2005-02-03
    The present invention relates to the use of EP1 receptor antagonists for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The invention also includes screening methods to identify compounds useful for the treatment of LUTS associated with BPH.
  • [EN] PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES<br/>[FR] COMPOSES PYRROLIQUES DESTINES AU TRAITEMENT DE MALADIES INDUITES PAR PROSTAGLANDINE
    申请人:GLAXO GROUP LTD
    公开号:WO2003101959A1
    公开(公告)日:2003-12-11
    Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
    式(I)的化合物或其药学上可接受的衍生物:其中A、R1、R2a、R2b、Rx、R8和R9如规范中所定义,一种制备这种化合物的方法,包括这种化合物的药物组合物以及这种化合物在医学中的用途,特别是它们在治疗前列腺素介导的疾病,如疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病中的用途。
查看更多